Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 31;9(3):ofab656.
doi: 10.1093/ofid/ofab656. eCollection 2022 Mar.

Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers

Yael Paran  1   2 , Esther Saiag  1   3 , Avishay Spitzer  1   4   5 , Yoel Angel  1   6   7 , Michal Yakubovsky  1   2 , Hagit Padova  1   8 , Ronen Ben-Ami  1   2 , Ilana Goldinger  1   9 , Ronni Gamzu  1   10 , Eli Sprecher  1   11   12 , David Zeltser  1   13 , Oryan Henig  1   2
Affiliations

Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers

Yael Paran et al. Open Forum Infect Dis. .

Abstract

This study demonstrated a favorable short-term safety profile after a third dose of the BNT162b2 vaccine among healthcare workers (HCWs). There were more frequent local reactions and less systemic reactions compared to the second dose. The HCWs who reported reactions had higher prebooster titer of anti-S1 antibodies compared to those who reported no reactions.

Keywords: BNT162b2; COVID-19; antibodies; booster; side-effects.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Third vaccine dose reactions. (B) Reaction to third dose vaccine in comparison to second vaccine dose (for the same vaccine participants).
Figure 2.
Figure 2.
Local and systemic reactions in the study cohort in comparison to reactions reported after the second dose.
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–15. - PMC - PubMed
    1. Haas EJ, Angulo FJ, McLaughlin JM, et al. . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021; 397:1819–29. - PMC - PubMed
    1. Dagan N, Barda N, Kepten E, et al. . BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021; 384:1412–23. - PMC - PubMed
    1. Angel Y, Spitzer A, Henig O, et al. . Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA 2021; 325:2457–65. - PMC - PubMed
    1. Barda N, Dagan N, Ben-Shlomo Y, et al. . Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2021; 385:1078–90. - PMC - PubMed